Trial · NCT04437511
Adverse events432
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 432
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Donanemab | 43 | 853 | 51 |
| other | Diarrhoea | Gastrointestinal disorders | Placebo | 50 | 874 | 56 |
| other | Fatigue | General disorders | Donanemab | 42 | 853 | 43 |
| other | Fatigue | General disorders | Placebo | 45 | 874 | 68 |
| other | Covid-19 | Infections and infestations | Donanemab | 130 | 853 | 135 |
| other | Covid-19 | Infections and infestations | Placebo | 150 | 874 | 157 |
| other | Urinary tract infection | Infections and infestations | Donanemab | 42 | 853 | 52 |
| other | Urinary tract infection | Infections and infestations | Placebo | 56 | 874 | 65 |
| other | Fall | Injury, poisoning and procedural complications | Donanemab | 111 | 853 | 149 |
| other | Fall | Injury, poisoning and procedural complications | Placebo | 109 | 874 | 141 |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Donanemab | 73 | 853 | 166 |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Placebo | 4 | 874 | 7 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Donanemab | 49 | 853 | 55 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Placebo | 41 | 874 | 44 |
| other | Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits | Nervous system disorders | Donanemab | 166 | 853 | 225 |
| other | Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits | Nervous system disorders | Placebo | 65 | 874 | 77 |
| other | Amyloid related imaging abnormality-oedema/effusion | Nervous system disorders | Donanemab | 200 | 853 | 270 |
| other | Amyloid related imaging abnormality-oedema/effusion | Nervous system disorders | Placebo | 17 | 874 | 17 |
| other | Dizziness | Nervous system disorders | Donanemab | 52 | 853 | 59 |
| other | Dizziness | Nervous system disorders | Placebo | 48 | 874 | 60 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04437511/events